Assessment of Glomerular Filtration Rate and End-Stage Kidney Disease Risk in Living Kidney Donor Candidates: A Paradigm for Evaluation, Selection, and.

Slides:



Advertisements
Similar presentations
From: Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney DiseaseA Secondary Analysis.
Advertisements

Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury  Yan Xie, Benjamin Bowe, Tingting Li, Hong Xian,
Kidney Disease Improving Global Outcome (KDIGO) classification of chronic kidney disease (CKD). Gradation of color from green to red corresponds to increasing.
Chronic Kidney Disease in Diabetes
Volume 80, Issue 1, Pages (July 2011)
Chronic Pain in End-Stage Renal Disease
Volume 80, Issue 1, Pages (July 2011)
Sheldon Chen  Advances in Chronic Kidney Disease 
Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury  Yan Xie, Benjamin Bowe, Tingting Li, Hong Xian,
Frederik Persson, Peter Rossing  Kidney International Supplements 
Simon Sawhney, Simon D. Fraser  Advances in Chronic Kidney Disease 
Estimated Glomerular Filtration Rate From a Panel of Filtration Markers—Hope for Increased Accuracy Beyond Measured Glomerular Filtration Rate?  Lesley.
Diabetic Kidney Disease: An ACEI (or an ARB) in the Hole
Evaluation of Kidney Donors: Core Curriculum 2018
Estimating GFR Using the CKD Epidemiology Collaboration (CKD-EPI) Creatinine Equation: More Accurate GFR Estimates, Lower CKD Prevalence Estimates, and.
Olivier Niel, MD, PhD, Charlotte Boussard, MSc, Paul Bastard, MSc 
Tariq Shafi, Andrew S. Levey  Advances in Chronic Kidney Disease 
Jesse C. Seegmiller, John H. Eckfeldt, John C. Lieske 
Section 2: AKI Definition
Core Assessment of Predonation Kidney Function: Clarification of the 2017 KDIGO Living Donor Guideline  Krista L. Lentine, MD, PhD, Andrew S. Levey, MD,
Metabolic Complications in Elderly Adults With CKD
Kidney International Supplements 
A Decade After the KDOQI CKD Guidelines
Simon Sawhney, Simon D. Fraser  Advances in Chronic Kidney Disease 
W. Greg Miller, Graham R.D. Jones  Advances in Chronic Kidney Disease 
Matei Neagu, PhD, Daniel Coca, PhD, Albert C.M. Ong, DM 
Corrections to "Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated.
Volume 80, Issue 1, Pages (July 2011)
John P. Middleton, Patrick H. Pun  Kidney International 
Haemorragic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: Do we need a novel risk score calculator?  Maura Ravera, Elisabetta.
GFR Estimation: From Physiology to Public Health
Improving Carboplatin Dosing Based on Estimated GFR
The Global Role of Kidney Transplantation
Advances in CKD Detection and Determination of Prognosis: Executive Summary of the National Kidney Foundation–Kidney Early Evaluation Program (KEEP) 2012.
William S. Asch, Margaret J. Bia  Advances in Chronic Kidney Disease 
Chapter 5: Referral to specialists and models of care
Your Kidneys May Outlive You
Cystatin C Versus Creatinine for GFR Estimation in CKD Due to Heart Failure  Delphine Kervella, MD, Sandrine Lemoine, MD, PhD, Florence Sens, MD, Laurence.
Chronic Pain in End-Stage Renal Disease
GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration 
Andrew S. Levey, MD, Hocine Tighiouart, MS, Andrew L
Comprehensive Public Health Strategies for Preventing the Development, Progression, and Complications of CKD: Report of an Expert Panel Convened by the.
Acute Kidney Injury and CKD: Chicken or Egg?
Utility and Validity of Estimated GFR–Based Surrogate Time-to-Event End Points in CKD: A Simulation Study  Tom Greene, PhD, Chia-Chen Teng, MS, Lesley.
The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli  Richard J. Glassock, Andrew D. Rule  Kidney.
The ESRD Uninsured Matter
On the Waterfront Advances in Chronic Kidney Disease
Volume 75, Issue 10, Pages (May 2009)
Joseph A. Vassalotti, MD, Lesley A. Stevens, MD, MS, Andrew S
Dinna N. Cruz  Advances in Chronic Kidney Disease 
Nephrology: As It Was Then, But Is Not Now
Performance of GFR Estimating Equations Stratified by Measured or Estimated GFR: Implications for Interpretation  Jonas Björk, PhD, Anders Grubb, MD,
Beef Tea, Vitality, Creatinine, and the Estimated GFR
Resolved: The Case for CKD Clinics
Volume 81, Issue 6, Pages (March 2012)
Evidence and Outcomes in CKD
The Kidney Effects of Hematopoietic Stem Cell Transplantation
A Fundamental Theorem of Telehealth
Daniel L. Landry, DO, FASN  Advances in Chronic Kidney Disease 
Methods for guideline development
Lesley A. Stevens, MD, MS, Nicholas Stoycheff, MD 
Volume 76, Issue 8, Pages (October 2009)
Current Concepts in Hemodialysis Vascular Access Infections
Michael J. Germain, MD, Sara N. Davison, MD, Alvin H. Moss, MD 
Improving Carboplatin Dosing Based on Estimated GFR
Lesley A. Stevens, MD, MS, Josef Coresh, MD, PhD, Andrew S. Levey, MD 
Internet Organ Solicitation, Explained
Patient Safety Issues in CKD: Core Curriculum 2015
Ann M. O'Hare, MA, MD  American Journal of Kidney Diseases 
Decision-Making in Patients With Cancer and Kidney Disease
Presentation transcript:

Assessment of Glomerular Filtration Rate and End-Stage Kidney Disease Risk in Living Kidney Donor Candidates: A Paradigm for Evaluation, Selection, and Counseling  Lesley A. Inker, Farrukh M. Koraishy, Nitender Goyal, Krista L. Lentine  Advances in Chronic Kidney Disease  Volume 25, Issue 1, Pages 21-30 (January 2018) DOI: 10.1053/j.ackd.2017.09.002 Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 The KDIGO framework to accept or decline donor candidates based on a transplant program's threshold of acceptable postdonation lifetime risk of kidney failure. A donor candidate's projected estimated lifetime risk is based on their predonation demographic characteristics (blue bar) and health characteristics (orange bar), and their risk attributable to donation (brown bar). The decision by the transplant program to accept or decline a donor candidate can be grounded upon on whether an individual's estimated projected postdonation lifetime risk is above or below the threshold set by the transplant program (dotted line). Each transplant program may decide on its acceptable threshold for an important outcome, and this threshold may vary across transplant programs, but a transplant program should apply their same threshold to all donor candidates evaluated at that center. For example, candidate A would be acceptable because the estimated projected postdonation risk for an important outcome is far below the threshold. Candidate B could be accepted with caution because the estimated projected postdonation risk is close to the threshold, and candidate C would be declined because the estimated postdonation projected risk is far above the threshold. KDIGO, Kidney Disease: Improving Global Outcomes. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) Reproduced with permission from KDIGO.11 Advances in Chronic Kidney Disease 2018 25, 21-30DOI: (10.1053/j.ackd.2017.09.002) Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions

Figure 2 KDIGO classification of GFR categories and use in decision-making for donor candidates. Colors are blended together to signify thresholds for decision-making are imprecise. GFR, glomerular filtration rate; KDIGO, Kidney Disease: Improving Global Outcome. Reproduced with permission from Levey and Inker, JASN.13 Advances in Chronic Kidney Disease 2018 25, 21-30DOI: (10.1053/j.ackd.2017.09.002) Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions

Figure 3 Assessment of GFR and application to donor candidate selection. Initial test: eGFRcr is the initial test in most donor candidates. eGFRcys may be the preferred initial test for candidates with variations in non-GFR determinants of eGFRcr, for example, variation in muscle mass or diet. Interpretation of eGFR should include consideration of the probability that mGFR is above or below thresholds for decision-making (http://ckdepi.org/equations/donor-candidate-gfr-calculator). Very high likelihood that mGFR is <60 mL/min/1.73 m2 is justification to decline without further evaluation. Confirmatory tests: mGFR or mCrCl is required in the United States. Elsewhere, eGFRcr-cys can be acceptable if mGFR or mCrCl is not available and eGFRcys was not used as the initial test. Repeat eGFRcr can be acceptable if none of the others confirmatory tests are available but is not preferred. Inconsistent test results suggest inaccuracy of one or more tests, which should be discarded or repeated. Very high likelihood that mGFR <60 mL/min/1.73 m2 is justification to decline without further evaluation. Using GFR to estimate long-term ESRD risk. Long-term estimated risk of ESRD is compared to the transplant program's threshold for acceptable risk. Long-term risk in the absence of donation can be estimated from demographic and health characteristics, including GFR (http://www.transplantmodels.com/esrdrisk). Additional risk attributable to donation is currently thought to be approximately 3.5-5.3 times higher than risk in the absence of donation, but there is substantial uncertainty, especially in younger donor candidates, and we suggest caution in decision-making. Postdonation ESRD risk above the program's acceptance threshold is justification to decline the candidate. Candidates with risk below the threshold are acceptable to the program, and make their own decision whether or not to proceed with donation. Colors are blended together to signify thresholds for decision-making are imprecise. GFR, glomerular filtration rate; mGFR, measured GFR. Reproduced with permission from Levey and Inker, JASN 2017.13 Advances in Chronic Kidney Disease 2018 25, 21-30DOI: (10.1053/j.ackd.2017.09.002) Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions

Figure 4 Perspectives of risk in living kidney donation. Framework for risk assessment and comparison relevant to the design of research studies, interpretation of observations, and patient communication. KDIGO, Kidney Disease: Improving Global Outcomes; LKD, living kidney donor. Reproduced with permission from KDIGO and JASN.11,31 Advances in Chronic Kidney Disease 2018 25, 21-30DOI: (10.1053/j.ackd.2017.09.002) Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions